Inducing Immune Response in Prostate Cancer with PTH-rP Peptide
Author Information
Author(s): Correale P, Micheli L, Vecchio M T Del, Sabatino M, Petrioli R, Pozzessere D, Marsili S, Giorgi G, Lozzi L, Neri P, Francini G
Primary Institution: University of Siena
Hypothesis
Can PTH-rP-derived peptides stimulate a specific cytotoxic T cell response in prostate cancer patients?
Conclusion
The study suggests that using PTH-rP peptide-pulsed dendritic cells can effectively stimulate an immune response against prostate cancer.
Supporting Evidence
- PTH-rP is a key agent for the development of bone metastases in prostate cancer.
- The study identified a peptide capable of generating a specific immune response.
- The T cell line showed cytotoxic activity against prostate cancer cells expressing PTH-rP.
Takeaway
Researchers found a way to help the body's immune system fight prostate cancer by using a special protein from the cancer itself.
Methodology
The study involved generating PTH-rP specific CTL lines from tumor-infiltrating lymphocytes through stimulation with IL-2 and peptide-pulsed dendritic cells.
Participant Demographics
HLA-A2.1+ individuals with metastatic prostate carcinoma.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website